All In Biotech

Drug Trial Radar · NCT06442761

SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Sickle Cell Disease Stem Cell Mobilization and Apheresis Using Motixafortide

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 14, 2024

Primary completion

Jan 2028

Study completion Jul 2028

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ayrmid Ltd
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. PRIMARY OBJECTIVE * To characterize the safety and tolerability of motixafortide in participants with SCD as determined by the incidence of adverse events (AEs). SECONDARY OBJECTIVES * To characterize the efficacy of a single dose (Part A) or two doses (Part B) of motixafortide for hematopoietic stem cell (HSC) mobilization and apheresis collection in participants with SCD as determined by the yield of CD34+ cells (CD34+ cells/kg). * To measure the mobilization effects of single-day (Part A) or daily dosing (Part B) dosing with motixafortide in the peripheral blood in participants with SCD as determined by peak peripheral blood CD34+ counts * To recommend a phase 2 dosing strategy based on safety, efficacy, and mobilization effects

Conditions

  • Sickle Cell Disease

Interventions

  • MotixafortideDrug

    Given Subcutaneously (under the skin).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of motixafortide in participants with sickle cell disease (SCD) as determined by the incidence of adverse events.Time frame: 0 - 30 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • National Heart, Blood and Lung Institute-Cellular and Molecular Therapy Branch

    Bethesda, Maryland · Recruiting

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.